Palisade Bio Announces Notice of Allowance for Canadian Patent Covering Lead Product Candidate, PALI-2108
11 juin 2024 08h30 HE
|
Palisade Bio, Inc.
PALI-2108 is orally delivered and colon-specific allowing for local activity with low systemic exposure Company on track to commence Phase 1 human clinical study of PALI-2108 for the treatment of...
Palisade Bio to Present at the Virtual Investor Pitch Conference
10 juin 2024 09h15 HE
|
Palisade Bio, Inc.
Live video webcast on Monday, June 17th at 12:00 PM ET Carlsbad, CA, June 10, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), biopharmaceutical...
Palisade Bio’s Lead Product Candidate, PALI-2108 Demonstrates Local Bioactivation and Dose Dependent Efficacy Response in Preclinical Mouse Models
21 mai 2024 08h30 HE
|
Palisade Bio, Inc.
Data presented at Digestive Disease Week (DDW) 2024 Preclinical data demonstrate PALI-2108 to be safe, effective, and well tolerated PALI-2108 is orally delivered and colon-specific allowing...
Aeterna Zentaris Announces Details Regarding Transaction with Ceapro
17 mai 2024 08h00 HE
|
Aeterna Zentaris Inc
TORONTO, ON, May 17, 2024 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”) announces that it has finalized certain details regarding the previously...
Aeterna Zentaris Reports First Quarter 2024 Financial Results
14 mai 2024 18h00 HE
|
Aeterna Zentaris Inc
Company ended the quarter with $29.5 million in cashDETECT-trial recruitment completed; Company continues to expect the completion of the trial in the second quarter and top-line data in the third...
Palisade Bio Reports First Quarter 2024 Financial Results and Provides Business Update
14 mai 2024 08h05 HE
|
Palisade Bio, Inc.
– Company on track to commence Phase 1 human clinical study of lead product candidate, PALI-2108, for the treatment of Ulcerative Colitis (UC) before year end – Sufficient cash on hand to...
Palisade Bio Appoints Margery Fischbein to its Board of Directors
07 mai 2024 08h30 HE
|
Palisade Bio, Inc.
Wall Street and biotech industry veteran with expertise across corporate finance, business development, M&A, licensing, and strategic alliance transactions, globally Carlsbad, CA, May ...
Palisade Bio Announces Closing of $4 Million Private Placement Priced At-The- Market Under Nasdaq Rules
07 mai 2024 07h30 HE
|
Palisade Bio, Inc.
Carlsbad, CA, May 07, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI), a biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with...
Palisade Bio Announces $4 Million Private Placement Priced At-The- Market Under Nasdaq Rules
02 mai 2024 08h30 HE
|
Palisade Bio, Inc.
Carlsbad, CA, May 02, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI), a biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with...
Palisade Bio’s Lead Product Candidate, PALI-2108 Demonstrates Potent Anti-Inflammatory Effects in Ex-Vivo Study of Whole Blood Samples Challenged with Pro-Inflammatory Lipopolysaccharide (LPS)
01 mai 2024 08h30 HE
|
Palisade Bio, Inc.
Company on track to commence Phase 1 human clinical study of PALI-2108 for the treatment of Ulcerative Colitis (UC) before year end Carlsbad, CA, May 01, 2024 (GLOBE NEWSWIRE) -- Palisade...